| Source: |
Escherichia coli. |
| Molecular Weight: |
Approximately 18.2 kDa, a single non-glycosylated polypeptide chain containing 166 amino acids. |
| AA Sequence: |
SKPIDVSRLD LRIGCIITAR KHPDADSLYV EEVDVGEIAP RTVVSGLVNH VPLEQMQNRM VILLCNLKPA KMRGVLSQAM VMCASSPEKI EILAPPNGSV PGDRITFDAF PGEPDKELNP KKKIWEQIQP DLHTNDECVA TYKGVPFEVK GKGVCRAQTM SNSGIK |
| Purity: |
> 98% by SDS-PAGE and HPLC analyses. |
| Biological Activity: |
Fully biologically active when compared to standard. The ED50 as determined by the apoptotic effect using serum free human MCF-7 cells is less than 40 ng/mL, corresponding to a specific activity of > 2.5 × 104 IU/mg. |
| Physical Appearance: |
Sterile filtered white lyophilized (freeze-dried) powder. |
| Formulation: |
Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH7.4. |
| Endotoxin: |
Less than 1 EU/μg of rHuEMAP-II as determined by LAL method. |
| Reconstitution: |
Centrifuge the vial briefly before opening to ensure that the contents settle at the bottom. Reconstitute the vial with sterile distilled water or an aqueous buffer containing 0.1% BSA to achieve a concentration of 0.1-1.0 mg/mL. Divide the resulting stock solution into working aliquots and store them at or below -20°C. For further dilutions, use appropriate buffered solutions. |
| Stability & Storage: |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month, 2 to 8°C under sterile conditions after reconstitution.
3 months, -20 to -70°C under sterile conditions after reconstitution. |
| Synonyms: |
SCYE1, EMAP-2, Small Inducible Cytokine Subfamily E Member 1 |
| Background: |
Endothelial-Monocyte Activating Polypeptide II (EMAP-II) is a cytokine originating from tumors that influences a broad spectrum of actions in endothelial cells, monocytes, and neutrophils. This substance hinders the growth of endothelial cells, the formation of new blood vessels, and can trigger cell death. Additionally, it acts as a chemical attractant for neutrophils and monocytes and stimulates the release of myeloperoxidase from neutrophils. Clinically, EMAP-II is significant for its ability to prevent the development of new blood vessels in vascular beds and to halt the progression of both primary and metastatic tumors, while sparing healthy tissue. The mature form of EMAP-II is a protein with a molecular weight of 18.3 kDa, produced from the C-terminal end of an inactive precursor protein that includes a propeptide with 146 amino acid residues. |
